IP Library Granted Patent US 11,207,412
Granted Patent B2
US 11,207,412 · App. 16/385,715 · Granted Dec 28, 2021

Viscosity reduction of highly concentrated protein formulations

Inventors: Martin Zillmann (Shrewsbury, MA); Alexandra Krog (Bodenheim, DE); Raphael Guebeli (Darmstadt, DE); Tanja Henzler (Mannheim, DE); Christian Hildebrandt (Heppenheim, DE)
Assignee: Merck Patent GmbH
A61K47/26A61K9/0095A61K9/19A61K47/183A61K47/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,207,412
App. No.
16/385,715
Granted
Dec 28, 2021
Kind
B2
Abstract

The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity. The contained proteins in the prepared formulations are stabilized against aggregation and denaturation and are thus sufficiently storage-stable until administration to the patient.

Claims (10)

1. A method for reducing the viscosity of a liquid formulation comprising a pharmaceutically active protein in a concentration in the range of at least 50 mg/ml up to 300 mg/ml, comprising combining the liquid formulation comprising protein with a viscosity-reducing concentration of one of the following combinations of excipients: meglumine+benzenesulfonic acid; ornithine+benzenesulfonic acid; ornithine+gluconic acid; ornithine+glucuronic acid; or mixtures of such combinations; wherein the amount of each of the excipients is from 50 to 150 mM.

2. The method of claim 1 , wherein the protein is selected from antibodies, antibody fragments, minibodies, modified antibodies, antibody-like molecules and fusion proteins.

3. The method of claim 1 , wherein the combination of excipients is meglumine and benzenesulfonic acid.

4. The method of claim 1 , wherein the combination of excipients is ornithine and benzenesulfonic acid.

5. The method of claim 1 , wherein the combination of excipients comprises meglumine and ornithine.

6. The method of claim 1 , wherein the combination of excipients comprises and one or more of benzenesulfonic acid, gluconic acid, and glucuronic acid.

7. The method according to claim 3 , wherein the meglumine and benzenesulfonic acid are added in equimolar amounts.

8. The method according to claim 1 , wherein viscosity of the formulation is reduced by at least 12%.

9. The method according to claim 1 , wherein viscosity of the formulation is reduced by at least 50%.

10. The method according to claim 1 , wherein viscosity of the formulation is reduced by at least 25%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2019
From: ZILLMANN, MARTIN; KROG, ALEXANDRA; GUEBELI, RAPHAEL; HENZLER, TANJA; HILDEBRANDT, CHRISTIAN
To: MERCK PATENT GMBH
Reel/Frame 049318/0228 →
Priority Claims (1)
EP 18167609 · Apr 16, 2018 · regional
Continuity (2)
Provisional Application 62666311 · May 3, 2018
Related Publication 20190314505A1 · Oct 17, 2019
Cited By (1)
US 12,350,340